Why Cardio Diagnostics Stock is Soaring Today

Cardio Diagnostics CDIO shares are trading higher after the company announced the launch of a new product.

What Happened: On Tuesday, Cardio Diagnostics announced the launch of its PrecisionCHD, an integrated epigenetic-genetic blood test of coronary heart disease. PrecisionCHD is the company’s second test built using the company’s proprietary AI-drive epigenetic-genetic engine.

PrecisionCHD can be utilized to increase accessibility to better care. The tests can be administered in provider settings or remotely through at-home testing and telehealth solutions.

Cardiovascular disease (CVD) continues to be the leading cause of death in the United States, with coronary heart disease being the most common form of CVD and the primary cause of heart attacks.

"The launch of PrecisionCHD represents a leap forward in cardiovascular medicine. I'm beyond thrilled that we're able to make the promise of precision cardiovascular medicine a reality," said Robert Philibert, MD Ph.D., the company's Chief Medical Officer and Co-Founder.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. Today’s trading volume is at 66.7 million at the time of publication, compared to the 100-day moving average of roughly 506,000.

According to data from Benzinga Pro, Cardio Diagnostics shares were up 143.5%, trading at $3.26 at the time of publication. The stock has a 52-week high of $5.25 and a 52-week low of $0.80.

Photo: StockSnap from Pixabay.